Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
- PMID: 8656254
- DOI: 10.1200/JCO.1996.14.6.1858
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
Abstract
Purpose and methods: The objective of this multicenter study was to compare the therapeutic index of two different doses of paclitaxel given as a 3-hour infusion in patients with metastatic breast cancer (MBC), who had failed to respond to previous chemotherapy. A total of 471 patients with MBC were randomized to receive intravenous paclitaxel at a dose of 175 or 135 mg/m2 every 3 weeks.
Results: Better treatment results were achieved with high-dose (HD) versus low-dose (LD) paclitaxel: overall response rate, 29% versus 22% (P = .108); complete response (CR) rate, 5% versus 2% (P = .088); median time to disease progression, 4.2 versus 3.0 months (P = .027); and median survival time, 11.7 versus 10.5 months (P = .321). Patients previously exposed or resistant to anthracyclines were as likely to respond as those without such prior exposure. Treatment was well tolerated, as documented by the number of administered treatment courses (median, six v five; range, one 17 v one to 18), the low frequency of dose reductions (14% v 7%, P = .024), and the small number of patients (n = 9 or 4% vn = 5 or 2%) who required treatment discontinuation for adverse reactions. The incidence and severity of neutropenia and peripheral neuropathy were dose-related. After quality-of-life-adjusted time-to-progression analysis, the HD arm (175 mg/m2) retained its advantage over the LD arm (135 mg/m2).
Conclusion: The results of this trial substantiate the activity of paclitaxel in the treatment of MBC. The observed superior efficacy with a dose of 175 mg/m2 over 135 mg/m2 suggests a dose-effect relationship. The clinical activity in anthracycline-resistant patients is particularly noteworthy. Paclitaxel in breast cancer needs further evaluation in large trials that use combination chemotherapy and involve earlier disease stages.
Comment in
-
Two doses of paclitaxel and statistical analysis: try, try, try again.J Clin Oncol. 1997 Jan;15(1):408-9. doi: 10.1200/JCO.1997.15.1.408. J Clin Oncol. 1997. PMID: 8996170 No abstract available.
Similar articles
-
Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.Semin Oncol. 1996 Oct;23(5 Suppl 11):32-7. Semin Oncol. 1996. PMID: 8893897 Clinical Trial.
-
Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.J Natl Cancer Inst. 1995 Aug 2;87(15):1169-75. doi: 10.1093/jnci/87.15.1169. J Natl Cancer Inst. 1995. PMID: 7674322 Clinical Trial.
-
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.J Clin Oncol. 1995 Oct;13(10):2575-81. doi: 10.1200/JCO.1995.13.10.2575. J Clin Oncol. 1995. PMID: 7595709 Clinical Trial.
-
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.J Clin Oncol. 1998 Oct;16(10):3353-61. doi: 10.1200/JCO.1998.16.10.3353. J Clin Oncol. 1998. PMID: 9779712 Review.
-
Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.J Infus Chemother. 1996 Summer;6(3):127-32. J Infus Chemother. 1996. PMID: 9229323 Review.
Cited by
-
Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer.J Oncol. 2012;2012:862921. doi: 10.1155/2012/862921. Epub 2012 Jan 15. J Oncol. 2012. PMID: 22291703 Free PMC article.
-
Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer.J Korean Med Sci. 2007 Sep;22 Suppl(Suppl):S115-21. doi: 10.3346/jkms.2007.22.S.S115. J Korean Med Sci. 2007. PMID: 17923737 Free PMC article. Clinical Trial.
-
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.Br J Cancer. 2004 May 4;90(9):1740-6. doi: 10.1038/sj.bjc.6601784. Br J Cancer. 2004. PMID: 15150624 Free PMC article. Clinical Trial.
-
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol. 2014 Oct 10;32(29):3307-29. doi: 10.1200/JCO.2014.56.7479. Epub 2014 Sep 2. J Clin Oncol. 2014. PMID: 25185096 Free PMC article.
-
Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo.Oncotarget. 2016 Jan 5;7(1):771-85. doi: 10.18632/oncotarget.5819. Oncotarget. 2016. PMID: 26506421 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials